Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Gynecol Pathol ; 40(4): 333-341, 2021 Jul 01.
Article in English | MEDLINE | ID: mdl-33021557

ABSTRACT

Most complete hydatidiform moles (CHMs) showcase an androgenetic nature of the nuclear genome. In the normal female embryo, one of the 2 X chromosomes is inactive. However, the status of X chromosome inactivation (XCI) in androgenetic CHMs remains unknown. Seventy-one androgenetic CHM tissues with the 46, XX karyotype were collected. Seventy-four normal female villi and 74 normal male villi were collected as controls. The expression of XCI markers (XIST, TSIX, and XACT) and an X-linked gene (CDX4) was detected by real-time polymerase chain reaction. Other XCI-associated genes were also examined, including the methylation status of the human androgen receptor gene (HUMARA) by methylation-specific polymerase chain reaction), and the expression of H3K27me3, USP21, and Nanog by Western blot and immunofluorescence, respectively. In addition, 126 CHMs and 63 normal female villous samples were collected for CDX4 immunohistochemical staining. The expression of XIST RNA was significantly lower, and TSIX RNA expression was significantly higher in androgenetic CHMs than that in normal female villi (both P<0.01). The expression of CDX4 mRNA in androgenetic CHMs was elevated compared with that in normal male and normal female villous samples (both P<0.01), and CDX4 protein expression was also higher than that in normal female villous samples (P<0.01). The expression of H3K27me3 was lower in androgenetic CHMs compared with that in normal female villi(P<0.01). The methylation pattern of HUMARA was found lacking in androgenetic CHMs. The expression of Nanog and UPS21 protein in androgenetic CHMs was higher than that in normal villi (both P<0.01). Both X chromosomes are active in androgenetic CHMs with the 46, XX karyotype, and the USP21-Nanog pathway may be involved in the disruption of XCI during this process.


Subject(s)
Hydatidiform Mole/genetics , RNA, Long Noncoding/genetics , Uterine Neoplasms/genetics , X Chromosome Inactivation/genetics , Androgens/metabolism , Chromosomes, Human, X/genetics , DNA Methylation , Female , Homeodomain Proteins/genetics , Humans , Hydatidiform Mole/pathology , Karyotype , Nanog Homeobox Protein/metabolism , Pregnancy , Receptors, Androgen/genetics , Trophoblasts/metabolism , Ubiquitin Thiolesterase/metabolism , Uterine Neoplasms/pathology
2.
Oncotarget ; 8(43): 75264-75271, 2017 Sep 26.
Article in English | MEDLINE | ID: mdl-29088863

ABSTRACT

Complete hydatidiform mole (CHM) is a rare pregnancy-related disease with invasive potential. The genetics underlying the sporadic form of CHM have not been addressed previously, but maternal genetic variants may be involved in biparental CHM. We performed whole-exome sequencing of 51 patients with CHM and 47 healthy women to identify genetic variants associated with CHM. In addition, candidate variants were analyzed using single base extension and Matrix Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry in 199 CHM patients and 400 healthy controls. We validated candidate variants using Sanger sequencing in 250 cases and 652 controls, including 205 new controls. Two single nucleotide polymorphisms, c.G48C(p.Q16H) inERC1 and c.G1114A(p.G372S) in KCNG4, were associated with an increased risk of CHM (p<0.05). These variants may contribute to the pathogenesis of CHM and could be used to screen pregnant women for this genetic abnormality.

3.
Gynecol Oncol ; 132(3): 745-51, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24486602

ABSTRACT

OBJECTIVE: The aim of this study was to characterize the clinical significance of GMFG, a novel ADF/cofilin superfamily protein, and investigate its role in cell migration and invasion in epithelial ovarian cancer (EOC). METHODS: The expression of GMFG in EOC tissues and ovarian cancer cell lines was evaluated by immunohistochemistry and immunoblotting respectively. The data were statistically analyzed for the associations of GMFG expression with clinicopathologic parameters and survival. In vitro cell migration and invasion assays were performed to determine the role of GMFG in cell migratory behaviors. The effect of GMFG on reorganization of actin cytoskeleton was investigated by immunostaining. RESULTS: GMFG was overexpressed in EOC. Up-regulated GMFG expression was closely correlated with advanced FIGO stage and chemoresistance of the disease. EOC patients with higher GMFG expression showed poorer progression-free survival (PFS) and overall survival (OS). In vitro cellular assays revealed that GMFG promoted cell migration and invasion. GMFG expression altered actin cytoskeleton organization probably by interacting with the Arp2/3 complex. CONCLUSION: GMFG expression independently predicts poorer prognosis in patients with EOC. Ectopic overexpression of GMFG contributes to the malignant biological behavior of ovarian cancer cells.


Subject(s)
Cell Movement/physiology , Glia Maturation Factor/biosynthesis , Neoplasms, Glandular and Epithelial/metabolism , Neoplasms, Glandular and Epithelial/pathology , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Actins/metabolism , Carcinoma, Ovarian Epithelial , Cell Line, Tumor , Cytoskeleton/metabolism , Cytoskeleton/pathology , Disease-Free Survival , Female , Formaldehyde , Glia Maturation Factor/genetics , Humans , Kaplan-Meier Estimate , Neoplasm Invasiveness , Neoplasms, Glandular and Epithelial/genetics , Ovarian Neoplasms/genetics , Paraffin Embedding , Prognosis , Tissue Fixation , Transfection
SELECTION OF CITATIONS
SEARCH DETAIL
...